May 14th 2025
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Watch the series now!
Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care
Colorectal Cancer Screening Gets Special Look in AJMC Papers